In May 2026, 5W AI Communications ran more than 60 patient and consumer prompts against ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, five times per engine, and tallied which pharmaceutical companies the answers named. Eli Lilly came out on top, with an estimated 12.5% share of citations. Merck, whose Keytruda is the best-selling drug on earth, ranked fifth, at 6%.[1][2] Three months earlier, IQVIA’s Consumer Health division had already built an entire webinar series around the same shift, walking clients through citation rates and AI Overview visibility for named brands.[5] Nine months before that, Real Chemistry, the agency behind campaigns for some of the largest drugmakers in the country, launched a standalone product to do this work full time.[3]
None of this happened quietly. It happened in press releases, webinar calendars, and agency capability decks, the ordinary public record of an industry building a new function. The question for any pharmaceutical marketing, medical affairs, or communications team reading this is not whether AI answer engines have become a channel worth measuring. That argument is over. The question is whether your organization is one of the ones already measuring it, or one of the ones showing up unmeasured in someone else’s competitive benchmarking report.
The Short Answer
Yes. A documented, growing set of pharmaceutical companies, agencies, and data vendors are already tracking how AI answer engines describe drugs, brands, and companies, and they are doing it at a pace that outstrips most internal marketing budgets. Real Chemistry, IQVIA, 5W AI Communications, and Klick Health have each built named products, practices, or published indices around AI citation tracking since August 2025.[3][5][1][6] The broader generative engine optimization (GEO) market that supports this work is estimated at roughly $850 million to $2.7 billion globally in 2026, depending on how narrowly “GEO platform” is defined, and every major forecaster projects double-digit to triple-digit compound annual growth through the early 2030s.[7][8][9] The rest of this article lays out the evidence, the numbers, and what a pharma team without a monitoring program is currently missing.
What Counts as “Tracking AI Drug Mentions”
The phrase covers a specific, measurable activity: running a defined set of prompts against a defined set of AI models on a recurring schedule, and recording which companies, drugs, and sources the models cite in response. It is not the same as running a chatbot pilot or asking ChatGPT a question once out of curiosity. It is a monitoring discipline with its own vocabulary, its own metrics, and, increasingly, its own vendor market.
From SEO to GEO
Generative Engine Optimization is the formal name for the discipline of earning citations inside AI-generated answers rather than rankings on a search results page. The term was coined in a peer-reviewed paper presented at the 2024 ACM SIGKDD conference by researchers at Princeton, Georgia Tech, the Allen Institute for AI, and IIT Delhi, who ran 10,000 queries across ten engines and found that specific content changes measurably shifted how often a source got cited.[11] By early 2026, GEO had moved from an academic paper to a line item in enterprise marketing budgets. 5W, the same firm behind the Pharma/Rx Index, now sells GEO as a standing practice area alongside public relations and digital marketing.[1]
The Four Things Being Measured
Every AI-visibility program tracks some combination of four variables: citation share (how often a company or drug is named relative to competitors across a prompt set), position (where in the answer the mention lands), sentiment or framing (whether the mention is neutral, favorable, or associated with a risk statement), and source (which underlying documents or websites the model is drawing from). Real Chemistry’s HealthGEO groups these under “LLM Perception Mapping” and “Competitive Benchmarking.”[3] 5W’s index reduces the same idea to a single number, citation share, tracked by company and by category.[1]
How This Differs From Traditional Media Monitoring and Share of Voice
Pharma companies have tracked media share of voice for decades. AI citation tracking is a different exercise because the “media” being monitored talks back in a structured, repeatable way. A journalist writes one article; an AI model can be asked the same question five times across five engines and may give five different answers, each pulling from a different mix of sources. AirOps’ 2026 State of AI Search analysis of 45,000 citations found that only 30% of brands maintain consistent visibility from one AI session to the next.[10] That instability is itself the reason monitoring has to be continuous rather than a one-time audit.
The Evidence: Who Is Already Doing This
The claim in this article’s title is not speculative. It is documented in press releases, product launches, and a published index with named methodology. Four examples, spanning agency, data, and consultancy sides of the industry, show the pattern.
Real Chemistry’s HealthGEO
Real Chemistry, a healthcare-focused AI and marketing communications firm, launched HealthGEO on August 21, 2025, describing it as the first healthcare-specific AI search analysis tool.[3] The platform runs prompt engineering and multi-model orchestration across ChatGPT, Gemini, Llama, and Claude, aggregating responses through what the company calls proprietary sentiment analysis.[3] By January 2026, Real Chemistry had expanded the offering into a broader corporate-reputation advisory practice, RC Resolve, pairing HealthGEO with a companion tool called ReputAI for reputation measurement and crisis message testing.[4] The expansion within five months signals this was not a one-off product launch but a growing service line with client demand behind it.
What HealthGEO Actually Tracks
According to the company’s own product description, HealthGEO performs four functions: mapping how a company, product, or therapeutic area is represented across leading LLMs; detecting hallucinations, outdated data, and reputational red flags; benchmarking AI share of voice against named competitors; and generating recommendations to align brand, medical, and commercial messaging with how generative AI models describe a topic.[3] Mary James, the company’s president of analytics and insights, offered a concrete illustration of the risk the tool is built to catch: a chatbot recommending once-daily dosing for a product whose label specifies twice-daily administration.[3]
5W AI Communications’ Pharma/Rx AI Visibility Index
5W is a public relations and digital marketing agency that has built an entire published research series, the AI Visibility Index, ranking brands by AI citation share across more than 39 industry categories, refreshed on a recurring cadence.[1] The Pharma/Rx edition, published in May 2026 and updated with a DTC-spend comparison in June 2026, ranks the top 25 pharmaceutical companies by citation share across five engines.[1][2] The firm explicitly frames this as a communications-strategy tool, not a clinical one, and its published playbook tells pharmaceutical communications teams to audit their own AI citation share quarterly.[1] That instruction, published for an industry-wide audience, is itself evidence that quarterly AI monitoring is becoming the expected baseline rather than an experimental extra.
IQVIA’s AI and Generative Search Practice
IQVIA, the largest healthcare data and analytics company serving the pharmaceutical industry, ran a dedicated Consumer Health webinar in February 2026 titled “AI & Generative Search: Reshaping Consumer Health and Wellness Marketing in 2026,” walking attendees through AI citation rates, AI Overview visibility, and competitive wins using named case studies from an online pharmacy and two other consumer brands.[5] The session’s stated conclusion was that early movers gain a lasting advantage in AI visibility, and that the foundations for that advantage need to be built now.[5] Coming from a company whose core business is selling competitive and commercial intelligence to pharma, a public push into AI-citation measurement is a signal about where the firm expects client demand to go next.
Klick Health’s Compliance-First AI Stack
Klick Health, one of the largest healthcare marketing agencies by revenue, built its 2025 to 2026 growth in part around AI tooling purpose-built for regulated pharma content, including Klick Guardrail, an internally developed compliance-reasoning tool, and a data lake called MedOcean integrating more than 30 sources for audience segmentation.[6] MM+M’s 2026 Agency 100 profile put Klick’s 2025 revenue at approximately $785 million, up nearly 19% year over year, with 91% of that growth coming from existing clients including Pfizer, Eli Lilly, and AstraZeneca.[6] The detail that matters here is not the AI tooling alone, but that it was built specifically to keep AI-generated content inside pharmaceutical compliance boundaries, which implies Klick’s own clients are already producing and monitoring AI-facing content at scale.
A Vendor Market Has Formed Around the Need
Beyond the four examples above, a broader software market has emerged to serve exactly this need. The GEO Platform Market, as tracked by Coherent Market Insights, splits into segments including GEO Software Platforms (47% share in 2026) and AI Visibility Monitoring specifically (35% share), the latter growing on the strength of enterprise demand for citation tracking as a standing function rather than a one-time project.[7] New entrants continue to launch through 2026: NeuroRank opened its AI visibility platform to the public in May 2026, and Pepper released an enterprise GEO platform in July 2026 aimed at brands optimizing for ChatGPT and Perplexity specifically.[7] None of these vendors is pharma-exclusive, but their existence confirms that the underlying demand for continuous AI citation tracking is broad enough to support a standalone software category, one that healthcare-specific tools like HealthGEO now sit inside.
Who Is Winning the AI Answer Right Now
The most concrete evidence available on pharma AI citation share is the 5W Pharma/Rx AI Visibility Index itself. Its methodology ran 60-plus prompts covering company identification, drug comparison, and category-leadership queries, five times per engine, across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, in Q2 2026.[1] The resulting ranking is the closest thing available to a public scoreboard for pharmaceutical AI visibility.
The Top 15 Pharmaceutical Companies by AI Citation Share
Rank
Company
Category
Est. AI Citation Share (Q2 2026)
1
Eli Lilly
Metabolic & GLP-1
12.5%
2
Novo Nordisk
Metabolic & GLP-1
11.5%
3
Pfizer
Diversified / vaccines
8.5%
4
Johnson & Johnson
Diversified
7.0%
5
Merck
Oncology
6.0%
6
AbbVie
Immunology & inflammation
5.0%
7
AstraZeneca
Oncology & specialty
4.0%
8
Moderna
Vaccines & mRNA
3.5%
9
Amgen
Biologics & specialty
3.0%
10
Novartis
Specialty & gene therapy
2.6%
11
Bristol Myers Squibb
Oncology & cardiovascular
2.3%
12
GSK
Vaccines & respiratory
2.0%
13
Sanofi
Immunology & vaccines
1.8%
14
Gilead Sciences
Antivirals & oncology
1.5%
15
Roche
Oncology & diagnostics
1.3%
Source: 5W AI Communications, Pharma/Rx AI Visibility Index 2026, Q2 2026 data window.[1] Share reflects the estimated proportion of company citations across 60-plus tracked patient and consumer prompts; figures are directional measures of relative visibility, not precise market measurement, per the index’s own methodology notes.
Revenue Rank Is Not Citation Rank
The index’s central and most citable finding is a structural mismatch: the companies with the highest AI citation share are not the companies with the highest pharmaceutical revenue.[1] Merck, AbbVie, and Pfizer sit among the industry’s largest companies by revenue, yet only Pfizer cracks the top three by citation share, and AbbVie sits sixth despite a decades-long run as one of the most heavily advertised pharmaceutical brands in the United States.[1]
Merck’s Keytruda Paradox
Keytruda is, by most industry accounts, the best-selling drug in the world. Merck still ranks fifth in AI citation share, at an estimated 6%, less than half of Eli Lilly’s share.[1] The index’s own explanation is that oncology drugs are prescribed by specialists rather than self-researched by patients typing questions into a chatbot, so a drug’s clinical and commercial dominance does not automatically translate into consumer-facing AI visibility.[1] That distinction matters for any brand team assuming sales rank and AI visibility move together.
The GLP-1 Citation Engine
Eli Lilly and Novo Nordisk lead the index because their GLP-1 drugs are among the most self-researched medications in recent memory. Consumers ask AI models to compare Ozempic, Wegovy, Mounjaro, and Zepbound by name, and those queries pull the parent companies into the answer alongside the drugs.[1] A separate 5W study, the Weight Loss & Metabolic Health AI Visibility Index published in May 2026, found that five GLP-1 receptor agonists together capture roughly 57% of all category citations in weight-loss and metabolic-health queries, with the four leading brands alone accounting for about 55%.[6]
Combined GLP-1 Sales and the $1 Trillion Milestone
The commercial scale behind that citation dominance is documented separately: Ozempic, Wegovy, Mounjaro, and Zepbound generated roughly $70 billion in combined 2025 sales, and Eli Lilly briefly crossed a $1 trillion market capitalization, becoming the first healthcare company to do so.[1] The AI citation data and the commercial data point in the same direction, which is itself a useful validation signal for anyone skeptical that citation share reflects anything real.
Where the Laggards Sit
The index also identifies categories of company that consistently underperform relative to their scale. Diversified conglomerates like Bayer, which splits its identity across pharmaceuticals, consumer health, and crop science, see their pharmaceutical citation share diluted by the surrounding business lines.[1] Privately held companies such as Boehringer Ingelheim generate less of the investor coverage, SEC filings, and news flow that feed AI citations, so they underindex relative to their actual market position.[1] Generic and biosimilar makers like Teva and Viatris are cited mainly in affordability and access queries rather than condition-specific ones, because AI answers about a specific disease route toward the branded originator by default.[1]
Why AI Citation Share Is Becoming a Commercial Metric, Not Just a Marketing Curiosity
The reason this topic has moved from marketing-conference novelty to board-level attention in under two years is that the underlying behavior change is measurable, and the commercial consequences are starting to show up in traffic and conversion data.
Patients Research Before the Appointment
5W frames this as the central dynamic reshaping pharma marketing: a growing share of patients now arrive at a physician’s office having already asked ChatGPT, Claude, or Google’s AI Overviews about their condition and their treatment options, making corporate AI citation share upstream of the prescription conversation itself.[1] Similarweb’s 2026 Generative AI Brand Visibility Index found that 35% of US consumers now use AI tools at the product discovery stage, compared with 13.6% who use traditional search for the same purpose.[10]
AI-Referred Traffic Converts at Multiples of Organic Search
Where data exists on what happens after a user clicks through from an AI answer, the conversion numbers are stark. Seer Interactive’s analysis found ChatGPT-referred visitors converting at 15.9%, compared with a 1.76% average conversion rate for Google organic search traffic, a gap of roughly nine times.[10] Ahrefs separately found that AI search visitors accounted for just 0.5% of total site traffic in its sample but generated 12.1% of signups, a 24-to-1 ratio relative to their traffic share.[10]
The Conversion-Rate Gap by Platform
Traffic Source
Conversion Rate
ChatGPT-referred visitors
15.9%
Perplexity-referred visitors
10.5%
Claude-referred visitors
5.0%
Google organic search (comparison baseline)
1.76%
Source: Seer Interactive, Google AI Overview Study, June 2025, as compiled in Omnibound’s 2026 GEO statistics review.[10][15]
Zero-Click Search Is Closing the Traditional Funnel
The flip side of high-converting AI referral traffic is a collapsing traditional search funnel. Similarweb found that zero-click searches on Google, meaning searches where the user never clicks through to a website, grew from 56% to 69% in the twelve months following the May 2024 launch of Google AI Overviews.[14][10] Organic traffic to news publishers fell from more than 2.3 billion monthly visits in mid-2024 to under 1.7 billion by May 2025, a loss of more than 600 million monthly visits in less than a year.[14]
Brand mentions correlate three times more strongly with AI visibility than backlinks do, at 0.664 versus 0.218 in an Ahrefs study spanning 75,000 brands.[12]
DTC Ad Spend Does Not Buy Citation Share
5W’s central structural finding is that the US pharmaceutical industry’s estimated $8 billion in 2024 direct-to-consumer advertising spend, the largest category-level DTC commitment in the country, does not predict which companies the AI engines actually cite.[1][2] AbbVie, Pfizer, and Bristol Myers Squibb rank among the highest individual DTC spenders, yet none of them leads the citation index.[1] The implication for brand teams used to buying visibility through media spend is that AI citation share runs on a different, largely earned-media mechanism, one that a television budget cannot purchase directly.
How Big Is the GEO Market, and How Fast Is It Growing
Multiple independent research firms have sized the generative engine optimization market in 2026, and while their absolute figures diverge sharply, their direction and growth-rate estimates converge.
Reconciling Divergent Market-Size Estimates
Research Firm
2025/2026 Market Size
Long-Range Forecast
CAGR
Coherent Market Insights (GEO Platform Market)
$2.70B (2026)
$26.85B (2033)
13.6%
Coherent Market Insights (GEO Services Market)
$1.25B (2026)
$13B (2033)
14.0%
IntelMarketResearch (GEO Services)
$1.01B (2025) / $1.48B (2026)
$17.02B (2034)
45.5%
MarketIntelo (GEO Market)
$848M (2025)
$19.8B (2034)
50.5%
Market Decipher (US GEO Market)
$365M (2026, US only)
$6.36B (2034, US only)
~43%
Sources: Coherent Market Insights, IntelMarketResearch, MarketIntelo, and Market Decipher industry reports, as published through mid-2026.[7][8][9]
Why the Numbers Disagree
The wide spread between a $365 million estimate and a $2.7 billion estimate for essentially the same year reflects scope differences rather than contradictory data. Narrower definitions count only standalone AI-visibility monitoring software; broader ones fold in AI content optimization services, GEO consulting, and adjacent digital marketing spend that has been relabeled for the AI era. What every forecaster agrees on, regardless of scope, is a compound annual growth rate in the double digits at minimum and the double-to-triple digits in several models, a trajectory Omnibound’s compiled statistics describe as consistent with an early-stage channel breakout.[10]
The Execution Gap: 92% Plan, 40.6% Act
The most operationally relevant statistic in this entire research area may be the gap between intention and execution. ConvertMate’s 2026 GEO Benchmark study, based on more than 12,500 queries across 8,000 domains, found that 92% of marketers across industries plan to optimize for AI search, but only 40.6% are currently doing so.[10] A separate measurement-specific survey found that only 23% of marketers are currently investing in GEO measurement at all, even among those who say they plan to.[10]
Why First-Mover Advantage Compounds
The gap between planning and doing matters because GEO citation authority behaves, according to the available research, the way domain authority did in the early years of SEO: it accumulates over time rather than resetting each quarter.[10] A company that starts building a monitored, structured, AI-citable content record in 2026 is not just ahead of a competitor that starts in 2028. It has two additional years of the freshness signals, source diversity, and earned-media citations that the underlying algorithms appear to weight, a lead that is structurally difficult for a late entrant to close quickly.
What the Research Says Actually Moves AI Citation Share
Beyond documenting that AI citation tracking exists, the available research offers specific, testable findings about what increases a brand’s odds of being cited.
Brand Mentions Outweigh Backlinks Three to One
The single most consequential finding for pharmaceutical communications teams comes from Ahrefs, which studied AI Overview visibility across 75,000 brands and found that raw brand mentions, meaning any editorial reference to a company name regardless of whether it includes a hyperlink, correlate far more strongly with AI visibility than traditional backlinks do.[12]
The Ahrefs Correlation Numbers
Brand mentions showed a 0.664 correlation with AI Overview visibility, compared with 0.218 for backlinks, a roughly three-to-one gap.[12] Branded anchor text sat in between at 0.527, and YouTube mentions were the single strongest off-site signal measured, at approximately 0.737 across ChatGPT, AI Mode, and AI Overviews combined.[12] The practical takeaway is that link-building, the core mechanic of a decade of SEO practice, is a weaker predictor of AI visibility than simply being talked about by name across a wide range of independent sources.
Statistics, External Citations, and Content Depth
The original Princeton/Georgia Tech/IIT Delhi KDD 2024 paper tested specific content interventions and found that adding statistics to a page improved its AI visibility by 41%, adding quotations improved it by 28%, and citing external sources improved visibility by as much as 115% for lower-ranked content specifically.[11][10] Notably, simply adding more words to a page produced no measurable improvement on its own; the signal the models respond to is data density and source credibility, not length.[10] A separate benchmark found that pages exceeding 20,000 characters received roughly 4.3 times more AI citations than pages under 500 characters, but the researchers attribute this to depth of evidence rather than word count in isolation.[10]
Freshness: Why a Quarterly Refresh Cycle Is Already Obsolete
AI-cited content is measurably fresher than content that ranks well in traditional organic search. One analysis found AI-cited pages were 25.7% fresher on average than their organic-search counterparts, and that ChatGPT shows the strongest recency bias of the major engines, with 76.4% of its most-cited pages having been updated within the prior 30 days.[10] Content updated within the last 30 days earned roughly 3.2 times more citations across platforms than stale content, while pages left unrefreshed for three months or longer were three times more likely to lose citations they had previously earned.[10] For a content team accustomed to a quarterly or annual review cycle for evergreen pages, this is a structural change in cadence, not a minor adjustment.
Earned Media Dominates the Citation Pool
Muck Rack’s analysis of more than one million links cited across ChatGPT, Claude, Gemini, and Perplexity between July and December 2025 found that 82% of AI citations come from earned media, meaning independent journalism, third-party editorial coverage, and organic mentions, with only about 6% coming from paid or owned brand content.[13][10] Journalism specifically accounted for 20% to 30% of all citations tracked.[13]
The 2% Overlap Problem
Muck Rack’s most actionable finding for communications teams is a mismatch: only about 2% overlap exists between the journalists PR teams typically pitch and the journalists whose work AI platforms actually cite.[13] The practical implication is that most pharmaceutical PR programs are optimized for a media landscape that predates the AI citation economy, and building AI visibility requires identifying and building relationships with a partially different set of outlets and writers than a traditional media list would surface.
The Accuracy Problem Sitting Underneath the Visibility Problem
Tracking how often a brand gets mentioned is only half the discipline. In a regulated industry, what the AI model says when it does mention a drug carries its own risk, separate from whether the mention happened at all.
What a 2026 Clinical Pharmacy Study Found
A study published in the Journal of the American College of Clinical Pharmacy in 2026 evaluated multiple clinically-focused AI chatbots, including tools specifically designed for medical and pharmaceutical use cases such as OpenEvidence, against licensed pharmacists answering real drug-information questions.[16] The researchers found that every AI chatbot tested, including the clinically-focused tools that outperformed general-purpose models like standard ChatGPT, still scored statistically lower than pharmacist-generated responses.[16] The study’s authors framed the finding as evidence that human pharmacist oversight remains essential to ensuring the accuracy of AI-generated drug information, even as purpose-built clinical AI tools improve.[16]
OpenEvidence vs General-Purpose Chatbots
The distinction the study draws between clinically-focused tools and general-purpose consumer chatbots matters for monitoring strategy. A pharmaceutical company’s AI-visibility program needs to track not just consumer-facing engines like ChatGPT and Google AI Overviews, but also the clinically-focused tools increasingly used by prescribers themselves, since an error surfaced to a physician carries a different risk profile than the same error surfaced to a patient doing preliminary research.
Why Visibility and Accuracy Are the Same Monitoring Discipline in Pharma
In most industries, a company that is not cited by an AI model simply misses a marketing opportunity. In pharmaceuticals, an AI model that does get a drug wrong, on dosing, contraindications, or drug interactions, creates a patient-safety issue that exists whether or not anyone at the company is watching. Real Chemistry built its dosing-error example, once-daily versus twice-daily recommendations, directly into its product marketing precisely because visibility monitoring and safety monitoring are functionally the same query set run against the same engines.[3] A company tracking citation share without also reviewing the content of those citations is measuring half the risk.
The Regulatory Backdrop: the January 2026 FDA-EMA Guiding Principles
On January 14, 2026, the FDA and the European Medicines Agency jointly published ten guiding principles for good AI practice across the drug development lifecycle, the first transatlantic regulatory alignment on AI in the pharmaceutical industry.[17][18] The principles emphasize a risk-based approach, clear context of use, data governance, lifecycle management, and clear essential information about how an AI system was built and validated.[17] The principles are non-binding and are focused primarily on AI used inside drug development rather than consumer-facing chatbots answering questions about approved drugs, but they establish a regulatory posture, transparency and risk-based oversight, that communications and medical affairs teams should expect to see extended toward AI-generated patient and provider information over time.[17][18]
What It Costs to Not Track This
The absence of a monitoring program is not a neutral position. It has specific, compounding costs that the evidence above makes concrete rather than hypothetical.
Ceding the Default Answer to Whoever Is Already Measured
When a patient or physician asks an AI model a question about a therapeutic category, the model answers using whatever sources it has been trained on or can retrieve, regardless of whether the company that owns the relevant drug is paying attention. A company not tracking its own AI citation share is not opting out of the conversation. It is simply not managing its side of a conversation that is happening anyway, one where AirOps’ research shows only 30% of brands maintain consistent visibility across sessions even when they are actively monitoring.[10] For an unmonitored brand, that inconsistency is invisible until a competitor, a journalist, or a regulator points it out.
Compliance Exposure From Unmonitored Claims
A pharmaceutical company operates under strict rules about what can be said publicly about its own products, on-label indications, fair balance, and approved claims chief among them. AI models summarizing information about a drug do not carry the same constraints, and can generate off-label suggestions, outdated dosing information, or unbalanced safety framing without any company representative having said a word.[3] Because these statements appear to patients and providers as though they came from a neutral source, the reputational and potentially regulatory exposure exists whether or not the company that owns the drug is watching.
The HealthGEO Dosing Example
Real Chemistry’s own illustration, a chatbot recommending once-daily dosing where the FDA label specifies twice-daily, is not a hypothetical edge case; it is the exact category of error the JACCP study found persisting even in clinically-focused AI tools built specifically to avoid it.[3][16] A monitoring program is the only mechanism by which a company learns this is happening before a patient does.
The Compounding-Authority Problem
Because AI citation authority accumulates the way domain authority did in traditional SEO, the cost of delay is not linear.[10] A competitor that has spent eighteen months building a monitored, continuously refreshed, source-diverse content record has an accumulated advantage that a new entrant cannot close by matching the current month’s activity. Every quarter without a monitoring program is a quarter a competitor’s lead widens, not merely holds steady.
What This Means for Medical Affairs
Medical affairs teams are typically the first to hear about AI-generated misinformation, usually from a field medical liaison or a medical information request flagging something a physician saw in a chatbot answer. A structured monitoring program converts that reactive pattern into a proactive one, surfacing label-discrepant claims, outdated indication information, or missing safety warnings before they reach a prescriber’s question at the point of care. The JACCP finding that even clinically-focused AI tools underperform pharmacists on accuracy suggests medical affairs teams should not assume that provider-facing AI tools are inherently safer than consumer-facing ones.[16]
What This Means for Brand and Commercial Teams
The 5W index data makes clear that DTC ad spend and AI citation share are not the same lever.[1] Brand teams accustomed to buying visibility through media placement need a separate strategy for earned AI visibility, one built around the mechanisms the research actually identifies: brand mentions across independent sources, statistic-dense and externally cited owned content, and a refresh cadence measured in weeks rather than quarters.[12][11][10] The conversion-rate data, ChatGPT-referred visitors converting at roughly nine times the rate of organic search traffic, gives commercial teams a direct revenue argument for treating this as a funded channel rather than an experimental one.[10]
What This Means for Regulatory and Compliance
The January 2026 FDA-EMA guiding principles signal a regulatory direction toward risk-based AI oversight, even though the current principles are focused on drug development rather than post-approval consumer information.[17][18] Compliance teams building AI-monitoring capability now, before consumer-facing AI oversight becomes formalized, are better positioned to demonstrate a documented, good-faith monitoring process if that oversight does extend in that direction. A monitoring program also generates the kind of internal audit trail, dated screenshots of what a model said and when, that is useful in the event a promotional-review or off-label inquiry ever touches AI-generated third-party content about a company’s own products.
What This Means for Competitive Intelligence
The 5W index itself is a competitive intelligence artifact: it tells a CI team exactly where its own company sits relative to every named competitor across a defined prompt set, refreshed quarterly.[1] A CI function that is not running its own version of this exercise, tailored to its specific therapeutic area and named competitors rather than a general industry index, is outsourcing a piece of its core function to whichever competitor or agency happens to publish comparable data. IQVIA’s decision to build named case studies around competitive AI-citation wins for specific consumer health brands shows that this kind of comparative tracking is already a deliverable clients are paying for.[5]
A Starting Framework for Monitoring AI Drug Mentions
Every example documented in this article, HealthGEO, the 5W index, IQVIA’s practice, and DrugChatter’s own AI monitoring work tracking label alignment and brand visibility for pharmaceutical clients, converges on a similar structural approach, even where the specific tooling differs.
Build Query Sets by Stakeholder, Not by Brand
A single prompt list is not sufficient because patients, healthcare providers, investors, and journalists ask fundamentally different questions and receive different answers even about the same drug. 5W’s own methodology explicitly separates company-identification, comparison, and category-leadership prompt types.[1]
Patient, HCP, Investor, and Journalist Prompts
A patient-facing query set should mirror the kind of question a consumer would actually type: “what is [drug] used for,” “[drug] vs [competitor],” “side effects of [drug].” A provider-facing set should test clinically-focused tools with dosing and interaction questions, the exact category where the JACCP study found persistent accuracy gaps.[16] Investor and journalist-facing prompts, less commonly tracked but increasingly relevant given how much AI citation activity draws on financial and news coverage, test how AI models summarize a company’s pipeline, trial readouts, and regulatory status.
Track Across Models, Not Just Across Brands
Domain overlap between different AI engines’ citation sources is low, one analysis of 100,000 prompts found only 11% overlap between the sources ChatGPT and Perplexity cite, because the underlying engines pull from different indexes: ChatGPT partly through Bing’s index, Perplexity through its own vector search, and Google AI Overviews through Google’s index directly.[10] A program that only monitors one engine is blind to what is happening on the others.
Separate a Visibility Audit From an Accuracy Audit
Citation share answers “are we being mentioned.” Accuracy review answers “is what’s being said correct.” The two require different reviewers, a marketing or communications lead for the first, a medical or pharmacovigilance reviewer for the second, and conflating them risks a program that catches a competitor outranking you but misses a mischaracterized contraindication in the same response.
Set a Re-Audit Cadence Tied to Regulatory and Trial Events
5W’s own playbook recommends re-auditing after every major launch, trial readout, or patent event, not on a fixed calendar alone, because each of those events materially reshapes what AI models retrieve and cite.[1] Given that content updated within 30 days earns roughly 3.2 times more citations than stale content, a monitoring cadence slower than monthly for high-priority therapeutic areas risks missing the window in which fresh, accurate information can outcompete outdated or competitor content in the same query space.[10]
Key Takeaways
Eli Lilly holds an estimated 12.5% share of pharmaceutical AI citations, the highest of any drugmaker, while Merck, maker of the world’s best-selling drug, ranks fifth at 6%, confirming that revenue rank and AI citation rank are not the same list.[1]
Real Chemistry launched a dedicated healthcare AI-visibility product, HealthGEO, in August 2025 and expanded it into a broader reputation-advisory practice by January 2026.[3][4]
The generative engine optimization market is estimated at roughly $850 million to $2.7 billion globally in 2026 depending on scope, with every major forecaster projecting double-digit to triple-digit compound annual growth through the early 2030s.[7][8][9]
92% of marketers across industries plan to optimize for AI search, but only 40.6% currently do, and only 23% invest in measurement specifically, leaving a wide execution gap for pharma teams to close before it compounds further.[10]
Brand mentions correlate roughly three times more strongly with AI visibility than backlinks do, and content refreshed within 30 days earns roughly 3.2 times more citations than stale content.[12][10]
A 2026 clinical pharmacy study found that even clinically-focused AI chatbots designed for medical use, including OpenEvidence, scored statistically lower than licensed pharmacists on drug-information accuracy.[16]
The January 2026 joint FDA-EMA guiding principles establish a risk-based, transparency-focused regulatory posture toward AI in drug development that communications and medical affairs teams should expect to see extended toward consumer-facing AI information over time.[17][18]
Frequently Asked Questions
What does “AI citation share” mean for a pharmaceutical company?
It is the estimated proportion of times a company or drug is named by an AI model across a defined set of tracked prompts, relative to how often competitors are named for the same queries. 5W’s index tracks this across five major engines using more than 60 patient and consumer prompts.[1]
Is DrugChatter’s monitoring approach different from a general marketing GEO tool?
General GEO platforms are built for any industry and typically focus on marketing visibility alone. Pharmaceutical-specific monitoring, including the kind of label-alignment and brand-visibility tracking DrugChatter builds for clients, layers a regulatory and safety review on top of citation tracking, checking not just whether a drug is mentioned but whether what is said matches the current FDA label.
Does more DTC advertising spend increase AI citation share?
Not directly. 5W’s index found that the pharmaceutical industry’s estimated $8 billion in 2024 DTC ad spend did not predict which companies led AI citation share; AbbVie, Pfizer, and Bristol Myers Squibb rank among the highest individual DTC spenders without leading the index.[1]
Which AI drug information errors are pharma companies most concerned about?
Dosing-frequency errors, outdated safety information, and off-label suggestions are commonly cited examples. Real Chemistry specifically points to a chatbot recommending once-daily dosing for a product labeled for twice-daily use as an illustrative risk.[3]
How often should a pharma brand re-check its AI visibility?
Industry guidance points toward at least a quarterly baseline audit, with additional re-audits triggered by major launches, trial readouts, or patent events, since content freshness data shows citations decay roughly three times faster on unrefreshed pages after three months.[1][10]
Do all AI engines cite the same sources?
No. One analysis of 100,000 prompts found only about 11% overlap between the sources ChatGPT and Perplexity cite for the same queries, reflecting the different underlying search and retrieval systems each engine uses.[10]
Are clinically-focused AI tools more accurate than consumer chatbots for drug information?
They tend to outperform general-purpose chatbots, but a 2026 study found that even clinically-focused tools like OpenEvidence still scored statistically lower than licensed pharmacists on drug-information accuracy, meaning human oversight remains necessary regardless of which tool is used.[16]
What is the difference between AI visibility monitoring and AI accuracy monitoring?
Visibility monitoring tracks whether and how often a brand or drug is mentioned. Accuracy monitoring reviews whether what is said is correct against the current label and clinical evidence. Both typically run against the same underlying prompt sets but require different reviewers and produce different outputs.
Has any regulator issued specific rules on AI-generated drug information for patients?
Not yet in a binding form specific to consumer-facing chatbots. The January 2026 joint FDA-EMA guiding principles focus on AI used within drug development and are explicitly non-binding, though they establish a risk-based oversight posture that could extend further.[17][18]
Is the generative engine optimization market pharma-specific?
No. GEO is a cross-industry discipline, with the broader platform and services market estimated at roughly $850 million to $2.7 billion globally in 2026 across all sectors. Healthcare-specific tools like HealthGEO exist within that broader market, adapted for regulatory and clinical requirements pharma brands face that other industries do not.[7][8][3]
References
5W AI Communications. “Pharma Rx AI Visibility Index 2026.” 5W Public Relations, May 2026. https://www.5wpr.com/ai-visibility-index/pharma-rx-ai-visibility-index-2026/
PR Newswire. “New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway.” June 19, 2026. https://www.prnewswire.com/news-releases/new-5w-ai-visibility-index-pharma-spends-billions-on-dtc-ads-the-ai-engines-talk-about-eli-lilly-and-novo-nordisk-anyway-302805664.html
Business Wire. “Real Chemistry Launches Healthcare-First AI Search Solution.” August 21, 2025. https://www.businesswire.com/news/home/20250821914816/en/Real-Chemistry-Launches-Healthcare-First-AI-Search-Solution
MM+M. “Real Chemistry Launches New Advisory Practice to Elevate Pharma’s Corporate Brand Reputation.” January 2026. https://www.mmm-online.com/news/real-chemistry-launches-rc-resolve-advisory-practice/
IQVIA. “AI & Generative Search: Reshaping Consumer Health and Wellness Marketing in 2026.” IQVIA Events, February 2026. https://www.iqvia.com/events/2026/02/ai-and-generative-search
MM+M. “Klick Health, 2026 Agency 100.” June 23, 2026. https://www.mmm-online.com/companydetail/klick-health-agency-100-2026/
MarketIntelo. “Generative Engine Optimization (GEO) Market Research Report 2034.” May 2026. https://marketintelo.com/report/generative-engine-optimization-geo-market
Omnibound. “Generative Engine Optimization Statistics (2026): 60+ Data Points on AI Citations, Brand Visibility, and Content Performance.” May 2026. https://www.omnibound.ai/blog/generative-engine-optimization-statistics
Princeton University, Georgia Tech, Allen Institute for AI, and IIT Delhi. “GEO: Generative Engine Optimization.” Presented at ACM SIGKDD 2024. https://collaborate.princeton.edu/en/publications/geo-generative-engine-optimization/
Ahrefs. “AI SEO Statistics: 75,000-Brand Study on Brand Mentions and AI Overview Visibility.” August 2025. https://ahrefs.com/blog/ai-seo-statistics/
Muck Rack. “What Is AI Reading? Earned Media Still Drives Generative AI Citations as Press Release Visibility Grows.” December 2025. https://www.globenewswire.com/news-release/2025/12/2/3198248/0/en/Earned-Media-Still-Drives-Generative-AI-Citations-as-Press-Release-Visibility-Grows.html
TechCrunch, citing Similarweb. “ChatGPT Referrals to News Sites Are Growing but Not Enough to Offset Search Declines.” July 2, 2025. https://techcrunch.com/2025/07/02/chatgpt-referrals-to-news-sites-are-growing-but-not-enough-to-offset-search-declines/
Seer Interactive. “Google AI Overview Study.” June 2025.
Ipema, H., Munir, F., Sarna, K., Wasynczuk, J., & Saiyad, Z. “Evaluation of Clinically-Focused Artificial Intelligence Chatbots for Answering Drug Information Questions.” Journal of the American College of Clinical Pharmacy, 9(6), e70231, 2026. https://pubmed.ncbi.nlm.nih.gov/42203638/
U.S. Food and Drug Administration and European Medicines Agency. “Guiding Principles of Good AI Practice in Drug Development.” January 14, 2026. https://www.fda.gov/media/189581/download
Regulatory Affairs Professionals Society (RAPS). “EMA, FDA Issue Joint AI Guiding Principles for Drug Developers.” January 14, 2026. https://www.raps.org/news-and-articles/news-articles/2026/1/ema-fda-issue-joint-ai-guiding-principles-for-drug
